Inhibiting menin, a protein that supports leukemia growth and is already targeted to treat some forms of leukemia, also holds ...

This group of cancers remains a challenge to diagnose, can be rapidly progressive, and requires complex treatment and follow-up care, research suggests. Despite recent advancements in treatments for ...

Clinical trials offer a unique treatment experience when you live with myeloproliferative disorders. Lower cost of care, direct access to a specialized MDS medical team, and the opportunity to try new ...

Dose-ranging ropeginterferon alfa-2b-njft (P1101) in PV targets complete hematologic response at week 24 using standard thresholds for hematocrit, leukocytes, and platelets. Rusfertide, a ...

A new form of CAR T cell therapy has been designed to find and destroy the cancer-driving stem cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while ...

MPNs encompass PV, ET, and myelofibrosis, each with unique symptoms and complications, requiring distinct management strategies. Treatment goals for MPNs focus on symptom control, risk reduction, and ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. So in MPNs, and this is what I tell my ...

Myeloproliferative neoplasm symptoms vary depending on the type a person has. Some symptoms include fatigue, headaches, fever, and unintentional weight loss. There are six types of chronic ...

Computed Tomography Scans Do Not Improve the Predictive Power of 1996 National Cancer Institute–Sponsored Working Group Chronic Lymphocytic Leukemia Response Criteria This study indicates that a ...